期刊文献+

29例男性乳腺癌临床分析 被引量:3

Clinical analysis of 29 cases of male breast cancer
暂未订购
导出
摘要 目的探讨男性乳腺癌的临床特征及影响预后的因素。方法回顾性分析2004年12月至2013年12月本院收治的29例男性乳腺癌患者的临床资料,应用Kaplan-Meier模型分析男性乳腺癌的生存情况。结果本组5年生存率为47.9%,2年生存率为81.2%。单因素分析示手术方式(P=0.026)、腋窝淋巴结转移(P=0.010)和肿瘤分期(P<0.001)影响患者预后。Cox回归多因素分析示肿瘤分期(P=0.037)是影响预后的主要因素。结论对男性乳腺癌应提高早期诊断率,一旦确诊应积极采取外科手术联合放、化疗、内分泌治疗提高患者的生存率。男性乳腺癌的预后与临床分期有一定关系。 Objective To discuss the clinical characteristics and prognostic factors of male breast cancer(MBC). Methods The clinical data of 29 male patients with breast cancer between December, 2004 and December, 2013 were collected and analyzed retrospectively. Survival rate was evaluated with KaplanMeier method. Results In this study, the 5-year overall survival rate was 47.9%, and the 2-year overall survival rate was 81.2%. Univariate analysis demonstrated that the prognoses of the patients were significantly influenced by the surgical options(P = 0.026), axillary lymph node metastasis(P = 0.010) and tumor stage(P〈0.001). Multivariate Cox regression showed that tumor stage(P = 0.037) was an independent prognostic factor for MBC. Conclusion The management of male breast cancer could be improved with early diagnosis. The surgical resection combined with radiotherapy, chemotherapy and endocrine therapy is the optimal treatment for male breast cancer. The prognoses of MBC correlates with the tumor stages.
作者 韩娜 王晓稼
出处 《分子诊断与治疗杂志》 2016年第1期23-26,共4页 Journal of Molecular Diagnostics and Therapy
基金 国家自然科学基金(81202806)
关键词 乳腺肿瘤 男性 临床特征 综合治疗 Breast cancer Male Clinical characteristics Combination therapy
  • 相关文献

参考文献21

  • 1Speirs V, Shaaban AM. The rising incidence of male breast cancer[J]. Breast Cancer Res Treat, 2009, 115(2): 429-430.
  • 2Siegel R, Ma J, Jemal A. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1):9-29.
  • 3Pant K, Dutta U. Understanding and management of male breast cancer: a critical review [J]. Med Oncol, 2008, 25(3):294-298.
  • 4Huang J, Tan PH, Thiyagarajan J, et al. Prognostic sig- nificance of glutathione s-transferase-pi in invasive breast cancer[J]. Mod Pathol, 2003, 16(6):558-565.
  • 5Rizzolo P, Silvestri V, Tommasi S, et al. Male breast cancer: genetics, epigenetics, and ethical aspects[J]. Ann Oncol, 2013, 24(8):75-82.
  • 6Qiu LX, Yao L, Xue K, et al. BRCA2 N372h polymor- phism and breast cancer susceptibility: a meta-analysis involving 44 903 subjects [J]. Breast Cancer Res Treat, 2010, 123(2):487-490.
  • 7Wasielewski M, den Bakker MA, van den Ouweland A, et al. CHEK2 1100delC and male breast cancer in the Netherlands[J]. Breast Cancer Res Treat, 2009, 116(2):397-400.
  • 8Nilsson C, Johansson I, Ahlin C, et al. Molecular sub- typing of male breast cancer using alternative definitions and its prognostic impact[J]. Acta Oncol, 2013, 52(1): 102-109.
  • 9Jepson AS, Fentiman IS. Male breast cancer[J]. Int J Clin Pract, 1998, 52(8):571-576.
  • 10Joshi MG, Lee AK, Loda M, et al. Male breast carcino- ma: an evaluation of prognostic factors contributing to a poorer outcome[J]. Cancer, 1996, 77(3):490-498.

同被引文献17

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部